Sunday, April 16, 2023 7:57:08 PM
Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.
Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.
Recent VRNA News
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 • GlobeNewswire Inc. • 05/02/2024 06:00:00 AM
- Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/25/2024 06:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/08/2024 09:18:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:40:38 AM
- Andrew Fisher Joins Verona Pharma as General Counsel • GlobeNewswire Inc. • 03/04/2024 07:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 02:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 11:08:57 AM
- Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 07:00:00 AM
- Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:11:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:10:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:19:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:07:24 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:02:48 AM
- Michael Austwick Joins Verona Pharma as Non-Executive Director • GlobeNewswire Inc. • 02/01/2024 07:00:00 AM
- Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 11:02:23 AM
- Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital • GlobeNewswire Inc. • 01/02/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:15:16 PM
- Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award • GlobeNewswire Inc. • 11/17/2023 07:00:00 AM
- Verona Pharma Announces November 2023 Investor Conference Participation • GlobeNewswire Inc. • 11/08/2023 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2023 12:11:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2023 12:09:56 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/03/2023 08:25:55 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM